Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.13 million versus the consensus estimate of $180 thousand.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.